AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$16.80
−$0.50 (−2.87%) 4:00 PM ET
After hours$16.64
−$0.16 (−0.98%) 2:51 AM ET
Prev closePrevC$17.30
OpenOpen$15.68
Day highHigh$17.42
Day lowLow$12.69
VolumeVol10,302
Avg volAvgVol10,727
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
P/E ratio
80.02
EPS
0.21
Sector
Financials
AI report sections
BULLISH
VACH
Voyager Acquisition Corp.
Voyager Acquisition Corp’s Class A shares show upward price momentum over the past six months alongside recent breakout-style technical signals, but intraday volatility and elevated short-volume ratios point to a potentially noisy trading environment. Fundamentally, the SPAC structure results in negative operating income, negative EBITDA, and negative equity even as net income and EPS remain positive on a trailing basis. Valuation metrics such as a high P/E multiple and deeply negative P/B and EV/EBITDA ratios indicate a complex profile that appears more driven by deal expectations than by current operating performance.
AI summarized at 2:09 AM ET, 2026-06-09
AI summary scores
INTRADAY:63SWING:67LONG:38
Volume vs average
Intraday (cumulative)
−100% (Below avg)
Vol/Avg: 0.00×
RSI
71.31(Overbought)
Overbought (>70)
0255075100
MACD momentum
Intraday
+0.00 (Neutral)
MACD: 0.00 Signal: 0.00
Short-Term
+0.80 (Strong)
MACD: 0.72 Signal: -0.09
Long-Term
+0.54 (Strong)
MACD: 0.34 Signal: -0.20
Intraday trend score
61.87
LOW61.87HIGH61.87
Latest news
VACH•5 articles•Positive: 3Neutral: 2Negative: 0
PositiveBenzinga• Not Specified
VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026
VERAXA Biotech AG successfully completed its business combination with Voyager Acquisition Corp and will begin trading on NASDAQ under ticker VRXA on June 11, 2026. The company secured $27.5 million in senior secured note financing and up to $50 million in share purchase agreements to advance its pipeline of BiTAC-TCE and BiTAC-ADC cancer therapies. VERAXA presented promising preclinical data at AACR 2026 demonstrating superior safety profiles and matching efficacy compared to traditional TCEs.
Successfully completed its stated mission of identifying and scaling a transformational healthcare company. The business combination closed as planned with shareholder approvals obtained, fulfilling the SPAC's objective.
PositiveGlobeNewswire Inc.• Na
VERAXA Biotech Strengthens Financial Position with $27.5 Million Principal Amount Senior Secured Note Financing and $50 Million Share Purchase Agreement
VERAXA Biotech has secured $27.5 million in senior secured note financing and a $50 million share purchase agreement with Lincoln Park Capital Fund to support its business combination with Voyager Acquisition Corp. and advance its pipeline of cancer therapies. VERAXA shareholders have approved the merger and issuance of new shares, with the combined company expected to list on NASDAQ under the ticker 'VRXA'.
Successfully completing a business combination with a well-funded biotech company focused on next-generation cancer therapies. The merger is progressing with shareholder approvals and regulatory filings, positioning Voyager to transition into a publicly traded healthcare company with a promising pipeline.
NeutralGlobeNewswire Inc.• Not Specified
VERAXA Biotech and Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology
VERAXA Biotech and Secarna Pharmaceuticals announced a strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs) for treating autoimmune and chronic immune diseases, combining their unique technology platforms.
Facilitating potential business combination with VERAXA Biotech without direct involvement in the research collaboration
PositiveGlobeNewswire Inc.• N/A
VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform
VERAXA Biotech, an emerging leader in cancer therapies, is attending the ASCO and BIO conferences to showcase its BiTAC platform and meet with potential partners and investors. The company is preparing to list on the NASDAQ later this year.
Voyager Acquisition Corp. is described as the proposed de-SPAC acquisition target for VERAXA Biotech, suggesting a positive outlook for the potential business combination and Voyager's involvement in VERAXA's growth.
NeutralGlobeNewswire Inc.• N/A
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program
VERAXA Biotech and OmniAb have entered a co-discovery alliance to develop a novel bispecific antibody drug conjugate program targeting solid tumors. The partnership combines VERAXA's ADC technology with OmniAb's antibody discovery solutions.
OABIOABIWVACHVACHUbispecific antibody drug conjugatesolid tumorsADC technologyantibody discovery
Sentiment note
The article mentions Voyager Acquisition Corp. as the proposed acquirer of VERAXA Biotech, but the focus of the article is on the co-discovery alliance between VERAXA and OmniAb, rather than the acquisition.
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
